Trial Profile
Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Pilot Study of the Rare Lymphoma Working Group
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Prednisone (Primary)
- Indications Adult T-cell leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 30 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2021 Interim Results (n=8) of safety and efficacy analysis, presented at the 63rd American Society of Hematology Annual Meeting and Exposition